Ceftriaxone and Tazobactam Injection

PACITREX-TZ is an advanced, combination antibiotic formulation by Pacitora Biotech containing Ceftriaxone (a third-generation cephalosporin) and Tazobactam (a potent beta-lactamase inhibitor) in a 1.125 gm vial. This powerful combination is indicated for the treatment of moderate to severe bacterial infections caused by beta-lactamase-producing resistant organisms, including many ESBL (extended-spectrum beta-lactamase) producers, that would not respond to ceftriaxone alone or even ceftriaxone-sulbactam combinations.

Many bacteria produce enzymes called beta-lactamases that destroy ceftriaxone and other antibiotics. Tazobactam is a more potent and broader-spectrum beta-lactamase inhibitor than sulbactam, capable of inactivating a wider range of these enzymes – including many ESBLs. This makes Pacitrex-TZ a valuable option for empiric therapy when resistance to other cephalosporins is suspected.

Key Benefits:

• Dual Action Against Resistant Bacteria – Ceftriaxone kills bacteria; Tazobactam protects it from beta-lactamase destruction.

• Overcomes Antibiotic Resistance – Tazobactam inactivates a broad range of beta-lactamase enzymes (including ESBLs).

• Enhanced Spectrum – Broader coverage than ceftriaxone alone or ceftriaxone-sulbactam combination.

• Broad-Spectrum Activity – Effective against Gram-positive, Gram-negative & many anaerobes.

• Treats Moderate to Severe Infections – Pneumonia, complicated UTI, intra-abdominal infections, sepsis, skin/soft tissue infections.

• Hospital-Acquired Infections – Empiric therapy for suspected ESBL-producing organisms.

FAQs:

1. What is the advantage of Pacitrex-TZ over Pacitrex-S (ceftriaxone-sulbactam)?
Tazobactam (TZ) is a more potent and broader-spectrum beta-lactamase inhibitor than sulbactam, providing enhanced coverage against many ESBL-producing organisms that may be resistant to ceftriaxone-sulbactam.

2. Can Pacitrex-TZ treat Pseudomonas aeruginosa?
No – ceftriaxone has very limited activity against Pseudomonas. For suspected Pseudomonas infections, piperacillin-tazobactam, ceftazidime, cefepime, or carbapenems are preferred.

3. Can Pacitrex-TZ treat MRSA?
No – Pacitrex-TZ is NOT effective against MRSA. Vancomycin, linezolid, or other MRSA-active agents are required for MRSA infections.

4. Is dose adjustment needed for Pacitrex-TZ in kidney disease?
Yes – for patients with severe renal impairment (CrCl <30 mL/min), dose adjustment is required. Always inform the physician of the patient’s kidney function before administration.